Intensity of SLX predicts distance of tumor spread through alveolar spaces in stage I lung adenocarcinoma.

Abstract:

BACKGROUND:Tumor spread through alveolar spaces (STAS) is a recently described invasive pattern associated with the prognosis and recurrence of lung adenocarcinoma. This study was performed to determine whether the presence and distance of STAS can be predicted by the immunohistochemical intensity of SLX, a well-known cell adhesion protein. METHODS:In total, 245 patients with pathological stage I lung adenocarcinoma who underwent lobectomy with radical mediastinal lymph node dissection were identified from 1998 to 2012. Recurrence-free survival (RFS) was compared between patients stratified by STAS and the immunohistochemical intensity of SLX in the main tumor. Patients were divided into three groups based on the intensity of SLX staining: high (n = 108), moderate (n = 48), and low (n = 89). RESULTS:STAS was observed in 71 patients (29.0%). Patients with STAS had significantly poorer five-year RFS (67.1%) than those without STAS (84.8%). Although no relationship was observed between the existence of STAS and SLX intensity, the distance between STAS cells and the main tumor was significantly shorter in the moderate group (median 0.9 mm, range: 0.2-1.2 mm) than in the other two groups (median 1.2 mm, range: 0.4-5.0 mm). The five-year RFS rates in the high, moderate, and low groups were 80.0%, 96.0%, and 75.8%, respectively. Multivariate analysis revealed that pathological stage, lymphatic/vascular invasion, and SLX intensity were independent predictors of recurrence. CONCLUSION:SLX staining cannot predict the presence of STAS; however, it can predict the distance between STAS and the main tumor in stage I lung adenocarcinoma.

journal_name

Thorac Cancer

journal_title

Thoracic cancer

authors

Hara K,Mizuguchi S,Okada S,Izumi N,Tsukioka T,Komatsu H,Ohsawa M,Inaba M,Shibata T,Nishiyama N

doi

10.1111/1759-7714.13008

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

832-838

issue

4

eissn

1759-7706

issn

1759-7714

journal_volume

10

pub_type

杂志文章
  • Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.

    abstract:BACKGROUND:If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK-tyrosine kinase inhibitors (ALK-TKIs) can be an effective treatment. However, the details of drug-induced lung injury (DILI) caused by ALK-TKI, which can be a serious side effect of ALK-TKIs, remains unclear. This study ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13416

    authors: Koshikawa K,Terada J,Abe M,Iwasawa S,Sakayori M,Yoshioka K,Hirasawa Y,Kasai H,Kawasaki Y,Tsushima K,Tatsumi K

    更新日期:2020-06-01 00:00:00

  • Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker.

    abstract:BACKGROUND:Tumor necrosis factor receptor 2 (TNFR2) promotes tumor cell proliferation, activates immunosuppressive cells, and supports immune escape. However, its role in non-small cell lung cancer (NSCLC) has not been reported. METHODS:Quantitative real-time PCR and Western blotting were used to evaluate TNFR2 in thr...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12948

    authors: Zhang YW,Chen QQ,Cao J,Xu LQ,Tang X,Wang J,Zhang J,Dong LX

    更新日期:2019-03-01 00:00:00

  • P16INK4a gene promoter methylation as a biomarker for the diagnosis of non-small cell lung cancer: An updated meta-analysis.

    abstract:BACKGROUND:This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lung cancer (NSCLC). METHODS:Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chine...

    journal_title:Thoracic cancer

    pub_type: 杂志文章,meta分析

    doi:10.1111/1759-7714.12783

    authors: Tuo L,Sha S,Huayu Z,Du K

    更新日期:2018-08-01 00:00:00

  • Salvage surgery using simultaneous clamshell thoracotomy with median sternotomy for mediastinal growing teratoma syndrome.

    abstract::This report describes the case of a 17-year-old man who developed mediastinal growing teratoma syndrome following two cycles of chemotherapy, after an initial diagnosis of primary mediastinal nonseminomatous germ cell tumor. The large, rapidly-growing mediastinal tumor was completely resected in conjunction with right...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13297

    authors: Kao CN,Chou SH,Huang CL,Lin CH,Chiang HH,Lee JY,Li HP,Chang PC,Liu YW

    更新日期:2020-03-01 00:00:00

  • Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.

    abstract:BACKGROUND:Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI ther...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13360

    authors: Mizuno T,Horinouchi H,Watanabe S,Sato J,Morita R,Murakami S,Goto Y,Kanda S,Fujiwara Y,Yamamoto N,Ohe Y

    更新日期:2020-04-01 00:00:00

  • Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.

    abstract::Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohisto...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12557

    authors: Okamura K,Fukuda Y,Soda H,Ogawara D,Iwasaki K,Fuchi S,Suyama T,Yoshida M,Harada T,Fukuda M,Mukae H

    更新日期:2018-01-01 00:00:00

  • Validated LC-MS/MS method of Sphingosine 1-phosphate quantification in human serum for evaluation of response to radiotherapy in lung cancer.

    abstract:BACKGROUND:Sphingosine 1-phosphate (S1P), a bioactive lipid, has been shown to mediate cancer processes. Therefore, accurate qualitative and quantitative determination is essential. The current assay method is still cumbersome to be of practical use worldwide and the aim of this study was therefore to develop a fast, a...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13409

    authors: Tang X,Chen H,Chen G,Duan C,Fan Q,Li H,Wang Y,Li Z,Shi W,Liu Y

    更新日期:2020-06-01 00:00:00

  • Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.

    abstract:BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better progno...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12791

    authors: Kang J,Chen HJ,Zhang XC,Su J,Zhou Q,Tu HY,Wang Z,Wang BC,Zhong WZ,Yang XN,Chen ZH,Ding Y,Wu X,Wang M,Fu JG,Yang Z,Zhang X,Shao YW,Wu YL,Yang JJ

    更新日期:2018-09-01 00:00:00

  • Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.

    abstract::Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first-line treatment option for extensive-stage small cell lung cancer (ES-SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first-line chemotherapy are limited,...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13588

    authors: Kataoka N,Kunimatsu Y,Tachibana Y,Sugimoto T,Sato I,Tani N,Ogura Y,Hirose K,Takeda T

    更新日期:2020-09-01 00:00:00

  • Metastatic meningeal carcinomatosis from lung cancer: Report of a rare case.

    abstract::Meningeal carcinomatosis (MC) refers to the diffuse or multifocal spread or infiltration of malignant tumors in the pia mater. It is a special distribution type of metastatic tumors in the central nervous system and one of the important reasons of death caused by metastatic malignant tumors. Here, we report a rare cas...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13243

    authors: Liu H,Liu L,Zhang X,Jin S

    更新日期:2020-01-01 00:00:00

  • Impact of target area selection in 125 Iodine seed brachytherapy on locoregional recurrence in patients with non-small cell lung cancer.

    abstract:BACKGROUND:Computed tomography (CT)-guided percutaneous implantation of 125 Iodine radioactive seeds requires the precise arrangement of seeds by tumor shape. We tested whether selecting target areas, including subclinical areas around tumors, can influence locoregional recurrence in patients with non-small cell lung c...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12415

    authors: Yan WL,Lv JS,Guan ZY,Wang LY,Yang JK,Liang JX

    更新日期:2017-05-01 00:00:00

  • Attempt of peripheral nerve reconstruction during lung cancer surgery.

    abstract:BACKGROUND:Vagus nerve and recurrent laryngeal nerve (RLN) injury are not rare complications of lung cancer surgery and can cause lethal consequences. Until now, no optimal method other than paying greater attention during surgery has been available. METHODS:Four patients underwent lung surgery that involved RLN or va...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12619

    authors: Li H,Hu Y,Huang J,Yang Y,Xing K,Luo Q

    更新日期:2018-05-01 00:00:00

  • Bronchomediastinal fistula detected accidently during palliative radiation therapy.

    abstract::Bronchomediastinal fistula is an extremely rare complication resulting from diseases such as mediastinitis or mediastinal malignancies. In patients with lung cancer, bronchomediastinal fistula formation has rarely been reported, except during post-chemotherapy or post-radiation therapy complications. An 84-year-old vi...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2012.00167.x

    authors: Song SH,Oh YJ,Chae SM,Lee J

    更新日期:2013-08-01 00:00:00

  • Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.

    abstract:BACKGROUND:Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non-small cell lung cancer (NSCLC). There is a lack of high-level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literatur...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13366

    authors: Song W,Di S,Liu J,Fan B,Zhao J,Zhou S,Chen S,Dong H,Yue C,Gong T

    更新日期:2020-04-01 00:00:00

  • Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.

    abstract:BACKGROUND:Immunotherapy is a new paradigm for the treatment of non-small-cell lung cancer (NSCLC), and targeting the PD-1 or PD-L1 pathway is a promising therapeutic option. Although PD-1/PD-L1 inhibitors are more effective than standard chemotherapy in lung cancer, clinicians are afraid to actively use them because o...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12877

    authors: Kang DH,Chung C,Kim JO,Jung SS,Park HS,Park DI,Jung SY,Park M,Lee JE

    更新日期:2018-11-01 00:00:00

  • Characteristics of the local recurrence pattern after curative resection and values in target region delineation in postoperative radiotherapy for lower thoracic esophageal squamous cell cancer.

    abstract:BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 t...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12499

    authors: Liu J,Cai X,Liu Q,Li H,Cheng Y,Fu X

    更新日期:2017-11-01 00:00:00

  • MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.

    abstract:BACKGROUND:Advanced non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. However, outcomes have gradually improved after the introduction of novel immunotherapies, including immune checkpoint inhibitors (ICIs). Although programmed death-ligand 1 (PD-L1) expression in tumor tissues is a known...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13653

    authors: Katakura S,Kobayashi N,Hashimoto H,Kamimaki C,Tanaka K,Kubo S,Nakashima K,Teranishi S,Manabe S,Watanabe K,Horita N,Hara Y,Yamamoto M,Kudo M,Piao H,Kaneko T

    更新日期:2020-10-01 00:00:00

  • Effects of periodontitis on postoperative pneumonia in patients with lung and esophageal cancer.

    abstract:BACKGROUND:Few studies have been conducted on the relationship between chronic periodontitis and postoperative pneumonia (POP) in patients with lung and esophageal cancer. Furthermore, it remains controversial as to whether improving the periodontal condition of patients with lung and esophageal cancer before surgery r...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13828

    authors: Jia C,Luan Y,Li X,Zhang X,Li C

    更新日期:2021-01-24 00:00:00

  • Immune checkpoint inhibitors-induced eosinophilic pneumonia: A case report.

    abstract::A 78-year-old male with renal cell carcinoma was treated with combined immunotherapy of nivolumab and ipilimumab. After four courses of the treatment, a chest computed tomography (CT) revealed newly formed ground-glass opacities (GGOs) in both the lower lung lobes; drug-induced pneumonia was speculated. Eosinophil cou...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13848

    authors: Hara K,Yamasaki K,Tahara M,Kimuro R,Yamaguchi Y,Suzuki Y,Kawabata H,Kawanami T,Fujimoto N,Yatera K

    更新日期:2021-01-21 00:00:00

  • Lung adenocarcinoma initially presenting as Trousseau's syndrome treated successfully with pembrolizumab: A case report.

    abstract::A 60-year-old woman was urgently admitted to our hospital because of vertigo and left hemiplegia. Laboratory examination showed thrombocytopenia, high levels of D-dimer and carcinoembryonic antigen. Brain magnetic resonance imaging (MRI) revealed multiple bilateral cerebral infarctions. Chest computed tomography (CT) ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13794

    authors: Nakano Y,Koide N,Koyama Y,Nitta K,Koizumi T

    更新日期:2020-12-21 00:00:00

  • HMGA2 regulates lung cancer proliferation and metastasis.

    abstract:BACKGROUND:This study aimed to explore the effects of HMGA2 on cell proliferation and metastases in lung cancer and its underlying mechanism. METHODS:HMGA2 expression in lung cancer tissues and its association with overall survival were analyzed based on data from a public database. The roles of HMGA2 were validated v...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12476

    authors: Gao X,Dai M,Li Q,Wang Z,Lu Y,Song Z

    更新日期:2017-09-01 00:00:00

  • Right upper lobectomy in lung cancer with double aortic arch: A case report.

    abstract::Double aortic arch (DAA) is a rare congenital anomaly of the heart and aorta in which a vascular ring that surrounds the trachea and esophagus is formed. In most patients, respiratory distress and dysphagia develop in childhood, and asymptomatic adult patients are rarely known. Herein, we describe a patient with lung ...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.13545

    authors: Kawamoto N,Okita R,Inokawa H,Hayashi M,Furukawa M,Okada M,Okabe K

    更新日期:2020-08-01 00:00:00

  • Flap endonuclease-1 rs174538 G>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population.

    abstract:BACKGROUND:Esophageal cancer has a high mortality rate, particularly in Asia, and there are obvious racial differences in regard to incidence. The purpose of our study was to assess the genetic susceptibility of functional single nucleotide polymorphisms in flap endonuclease-1 (FEN1) in esophageal squamous cell carcino...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12422

    authors: Sang Y,Bo L,Gu H,Yang W,Chen Y

    更新日期:2017-05-01 00:00:00

  • Metastasis in the subcarinal lymph node with unknown primary tumor.

    abstract::A 59-year-old man with previous anaplastic large cell T-cell lymphoma stage 3A was admitted with an isolated positron emission tomography(PET)-positive spot in a subcarinal lymph node. Diagnosis was achieved with endobronchial ultrasound-guided fine-needle aspiration demonstrating a well-differentiated squamous cell c...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/j.1759-7714.2010.00039.x

    authors: Eckardt J,Olsen KE,Petersen H

    更新日期:2011-05-01 00:00:00

  • Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma.

    abstract:BACKGROUND:The five-year survival rate of lung adenocarcinoma patients (LUAD) is very low,and the methods of predicting survival are a great obstacle for LUAD therapies. Endothelin receptor type B (EDNRB) gene is associated with tumorigenesis. In this study, we aimed to evaluate the predictive value of EDNRB on LUAD. ...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.13474

    authors: Wei F,Ge Y,Li W,Wang X,Chen B

    更新日期:2020-07-01 00:00:00

  • Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.

    abstract:BACKGROUND:Many randomized clinical trials have demonstrated that epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are advantageous over standard chemotherapy, either as front-line treatment or as further management of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Howev...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12275

    authors: Sun H,Sun X,Zhai X,Guo J,Liu Y,Ying J,Wang Z

    更新日期:2016-01-01 00:00:00

  • Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

    abstract:BACKGROUND:In cases of EGFR-tyrosine kinase inhibitor (TKI) failure, re-biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re-biopsy is challenging because of several hurdles. We assessed the feasibility of re-biopsy in advanced non-small cell lung cancer...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12762

    authors: Kim TO,Oh IJ,Kho BG,Park HY,Chang JS,Park CK,Shin HJ,Lim JH,Kwon YS,Kim YI,Lim SC,Kim YC,Choi YD

    更新日期:2018-07-01 00:00:00

  • Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: A multicenter real-world observational study.

    abstract:BACKGROUND:Approximately 8.3-15.9% of patients with clinical stage I non-small cell lung cancer are subsequently shown to have lymph node metastasis. However, the clinical characteristics of patients with lymph node metastasis in China are not fully understood. METHODS:This is a multicenter retrospective analysis of p...

    journal_title:Thoracic cancer

    pub_type: 杂志文章

    doi:10.1111/1759-7714.12970

    authors: Chen B,Wang X,Yu X,Xia WJ,Zhao H,Li XF,Liu LX,Liu Y,Hu J,Fu XN,Li Y,Xu YJ,Liu DR,Yang HY,Xu L,Jiang F

    更新日期:2019-03-01 00:00:00

  • Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma.

    abstract::A 57-year-old man was admitted to our department 10 years ago, diagnosed with tracheal adenoid cystic carcinoma. After discontinuing chemotherapy and radiotherapy, the disease recurred in December 2016. Apatinib mesylate (500 mg/day) was administered and computed tomography revealed that his symptoms were significantl...

    journal_title:Thoracic cancer

    pub_type:

    doi:10.1111/1759-7714.12506

    authors: Wang H

    更新日期:2017-11-01 00:00:00

  • Survival in early lung cancer patients treated with high dose radiotherapy is independent of pathological confirmation.

    abstract:BACKGROUND:Approximately 15% of lung cancer patients are diagnosed in early stages. Microscopic proof of disease cannot always be obtained because of comorbidity or reluctance to undergo invasive diagnostic procedures. In the current study, survival data of patients with and without pathology are compared. METHODS:One...

    journal_title:Thoracic cancer

    pub_type: 临床试验,杂志文章

    doi:10.1111/1759-7714.12966

    authors: Zehentmayr F,Sprenger M,Rettenbacher L,Wass R,Porsch P,Fastner G,Pirich C,Studnicka M,Sedlmayer F

    更新日期:2019-02-01 00:00:00